Vered Caplan
Chief Executive Officer at ORGENESIS INC.
Net worth: 140 208 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hugues Bultot | M | 58 |
MaSTherCell SA
 MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | 13 years |
| Ohad Karnieli | M | - |
Orgenesis Biotech Israel Ltd.
 Orgenesis Biotech Israel Ltd. Medical/Nursing ServicesHealth Services Orgenesis Biotech Israel Ltd. provides process development capabilities, custom engineering, platform design and optimization and cells and viruses cyclic guanosine monophosphate manufacturing services. The firm also offers assay devlopment and validation services. The company was founded by Ohad Karnieli and is headquartered in Nesher, Israel.
MaSTherCell SA
MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | - |
| David Sidransky | M | 64 | 11 years | |
| Mario Philips | M | 54 | 4 years | |
| Yaron Adler | M | 54 | 12 years | |
| Guy Yachin | M | 55 | 12 years | |
| Sarah Ferber | M | 70 | 16 years | |
| Ashish Nanda | M | 59 | 7 years | |
| Victor Miller | M | 54 | - | |
| Shimon Hassin | M | - |
MaSTherCell SA
MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | - |
| Heiko von der Leyen | M | - | 4 years | |
| Gerhard Bauer | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Neil Reithinger | M | 54 | 9 years | |
| Guilbert Cuison | M | 55 | - | |
| Elliot Maltz | M | 39 | - | |
| Joseph Tenne | M | 68 | - | |
| Dov Weinberg | M | 71 | 2 years | |
| Osher Rheinisch | F | 52 | 1 years | |
| Sav DiPasquale | M | 62 | 1 years | |
| Steven Katz | M | 76 |
Gammacan International, Inc.
 Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 years |
| Etti Hanochi | F | 50 | 5 years | |
| David S. Frank | M | 79 | 3 years | |
| Claudia Zylberberg | M | - | - | |
| Jerome Golez | M | 54 | - | |
| Efrat Assa-Kunik | M | 49 | 2 years | |
| Marie Bouillez | F | 43 | - | |
| Dan Jacob Gelvan | M | 59 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | - |
| Jacob BenArie | M | 55 | - | |
| Christopher Greenwood | M | 44 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 4 years |
| Josef Neuhaus | M | 60 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 years |
| Tovi Ben Zeev | F | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | - |
| Chris Buyse | M | 59 | 1 years | |
| Patrick Schnegelsberg | M | 60 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 years |
| Albert Passner | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 years |
| Gutman Lior Soussan | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 1 years |
| Jean-Pierre Elisha Martinez | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | - |
| Chaime Orlev | M | 53 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 25 | 67.57% |
| Israel | 11 | 29.73% |
| Belgium | 3 | 8.11% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Vered Caplan
- Personal Network
